Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

A legfontosabb adatok

Ki végzi
Liaquat University of Medical & Health Sciences
Hol
Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
289 fő vett részt
Kezdés
2023. jan. 2.
Befejezés
2024. dec. 15.
A vizsgálat típusa
Megfigyeléses, 3 csoport
A vizsgált kezelések
  • AHCC® (Active Hexose Correlated Compound)
  • Gardasil 9®
A regiszteradat frissítve
2026. január 28.

Ki vehet részt

Életkor
18 év felett
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Female participants aged 18 years or older
  • Documented persistent high-risk HPV infection for at least 6 continuous months, confirmed by consecutive HPV-DNA tests
  • Absence of high-grade cervical lesions (≤ CIN1)
  • Availability of complete clinical records with evaluable HPV-DNA testing at baseline and follow-up
  • Documented management with AHCC® supplementation alone, nonavalent HPV vaccination alone, or combined AHCC® supplementation and nonavalent HPV vaccination in routine clinical practice
  • No prior excisional or ablative treatment of the cervix (including conization or LEEP)

Ki nem vehet részt

  • History of cervical excisional or ablative treatment (including conization or LEEP)
  • Presence of high-grade cervical lesions (CIN2 or worse) or invasive cervical cancer
  • Conditions known to significantly alter immune function, including ongoing immunosuppressive therapy, active autoimmune disease requiring systemic treatment, or documented immunodeficiency, when such information was available in medical records
  • Prior systemic antiviral or immunomodulatory therapy specifically aimed at HPV clearance during the observation period
  • Incomplete clinical documentation or missing HPV follow-up data

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a retrospective, multicenter, observational study evaluating real-world HPV-DNA clearance in women with documented persistent high-risk HPV infection lasting at least six months. Clinical data were retrospectively collected from medical records of women managed in routine practice with one of three strategies: AHCC® supplementation alone, nonavalent HPV vaccination alone, or the combination of AHCC® supplementation and nonavalent HPV vaccination. The primary objective is to assess HPV-DNA clearance at 4 and 6 months following treatment initiation.

A vizsgálat 3 csoportja

  • Unvaccinated with AHCC® Supplement

    Women previously managed in routine clinical practice with AHCC® supplementation alone for persistent HPV infection. Participants had not received HPV vaccination prior to treatment. Clinical data were retrospectively collected from medical records to evaluate HPV-DNA clearance following this real-world management strategy.

    Kezelés: AHCC® (Active Hexose Correlated Compound)

  • Vaccinated with AHCC® Supplement

    Women previously managed in routine clinical practice with combined AHCC® supplementation and nonavalent HPV vaccination for persistent HPV infection. Treatments were prescribed as part of standard care. Clinical data were retrospectively collected to assess HPV-DNA clearance following combined real-world exposure.

    Kezelés: AHCC® (Active Hexose Correlated Compound) és Gardasil 9®

  • Vaccinated Only

    Women previously managed in routine clinical practice with nonavalent HPV vaccination alone for persistent HPV infection. No AHCC® supplementation was used. Clinical data were retrospectively collected to assess HPV-DNA clearance following vaccination as standard care.

    Kezelés: Gardasil 9®

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the Efficacy and Safety of an AHCC®-Based Supplement (Lentinula Edodes) in Promoting Negativity of Persistent HPV Infection: A Retrospective Multicenter Clinical Study
A regiszteradat frissítve
2026. január 28.